Advertisement

TBIO

Telesis Bio, Inc.

Healthcare · USD

Set alert

Price alert · TBIO

All alert types
0.04 USD 0.00 0.00%
As of Oct 29, 2026
0.01155 Day range 0.01155
0.0001 52-week range 0.11
YTD
-22.80%
1 year
+221.67%
Open
0.01155
Prev close
0.0386
Mkt cap
68.55K
Vol
3
Avg vol
281
EPS
-22.99
P/E
0.00
Div yield
0.00%
More statistics
Low
0.01155
High
0.01155
Forward P/E
-0.07
Beta
0.00
Short ratio
0.42
Inst. own
31.50%
Dividend
0.00
Ex-div date
50-d avg
2.47
200-d avg
4.85
1y target
0.00

2Y chart

Chart tools
Interval
TBIO two-year price chart0.000.390.781.161.55Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
2.27M
Enterprise value
38.99M
Trailing P/E
0.00
Forward P/E
-0.07
PEG ratio
0.00
Price / sales
0.15
Price / book
0.00
EPS (TTM)
-30.42
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-292.59%
Revenue (TTM)
15.57M
Revenue growth
-71.90%
Free cash flow
-12.21M
Total cash
4.51M
Total debt
10.45M
Return on equity
-176.11%
Shares outstanding
1.77M
Short % of float
7.31%
50-day average
2.47
200-day average
4.85

Analyst view

Consensus: buy

Buy
Price target (mean) 0.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate -6.58.

Earnings history

Financials — quick view

All financials
TBIO Revenue — quarterly 1.55M
2020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 2024
TBIO Net income — quarterly -12.59M
2020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 2024
TBIO EPS — quarterly -7.62
2020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 2024

Earnings

TBIO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 20240.00-3.83——
Aug 7, 2024Jun 1, 20240.00-7.03——
May 9, 2024Mar 1, 20240.00-99.28——
Mar 28, 2024Dec 1, 2023-4.50-4.14+0.36+8.00%
Nov 13, 2023Sep 1, 2023-5.22-6.65-1.43-27.39%
Aug 10, 2023Jun 1, 2023-4.86-5.04-0.18-3.70%

Upgrades / downgrades

TBIO analyst upgrades and downgrades
DateFirmActionFromTo
Aug 10, 2023KeybancdownOverweightSector Weight
Nov 8, 2022Keybancmain—Overweight
Mar 27, 2022Keybancmain—Overweight
Jul 12, 2021Keybancinit—Overweight
Jul 12, 2021Cowen & Co.init—Outperform
Jul 12, 2021Jefferiesinit—Buy

About Telesis Bio, Inc.

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on TBIO — it syncs with the Stock Master app.

Insider holders

TBIO insider holders
InsiderRelationLatest transactionDateShares held
GOLUB STEVEN JDirectorStock Award(Grant)Jul 23, 20248,390
HERREMA GREGORY JDirectorStock Award(Grant)Apr 30, 2024184,677
HLAVINKA SARAH EDirectorStock Award(Grant)Jul 23, 20248,390
HODGES MICHAELDirectorStock Award(Grant)Jul 23, 20248,390
KRUEGER TODDDirectorStock Award(Grant)Jul 23, 20248,390
NACHTSHEIM JAMI DOVER KDirectorStock Award(Grant)Apr 30, 2024101,679

Institution ownership

TBIO institution ownership
Holder% heldSharesValueReported
Northpond Ventures, Llc32.87%9,844,13015.55MJun 29, 2023
Penn Capital Management Co., Inc.1.94%579,522915.64KJun 29, 2023
Vanguard Group Inc1.43%427,202674.98KJun 29, 2023
Penbrook Management LLC1.21%363,570378.11KSep 29, 2023
Millennium Management Llc0.84%251,670397.64KJun 29, 2023
Bridgeway Capital Management, Inc.0.39%117,000184.86KJun 29, 2023

Fund ownership

TBIO fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.03%307,523485.89KJun 29, 2023
Bridgeway Funds Inc-Ultra Small Company Market Fund0.39%117,000184.86KJun 29, 2023
Vanguard Extended Market Index Fund0.37%110,770175.02KJun 29, 2023
Fidelity Extended Market Index Fund0.13%38,86662.19KMay 30, 2023
iShares Micro Cap ETF0.08%24,06031.28KAug 30, 2023
Fidelity Series Total Market Index Fund0.04%11,53018.45KMay 30, 2023
Advertisement